Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study

Low-molecular weight heparin (LMWH) has been the standard of care for treatment of venous thromboembolism (VTE) in patients with cancer. Rivaroxaban was approved in 2012 for the treatment of pulmonary embolism (PE) and deep vein thrombosis (DVT), but no prior studies have been reported specifically...

Descripción completa

Detalles Bibliográficos
Autores principales: Mantha, Simon, Laube, Eva, Miao, Yimei, Sarasohn, Debra M., Parameswaran, Rekha, Stefanik, Samantha, Brar, Gagandeep, Samedy, Patrick, Wills, Jonathan, Harnicar, Stephen, Soff, Gerald A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318467/
https://www.ncbi.nlm.nih.gov/pubmed/27696084
http://dx.doi.org/10.1007/s11239-016-1429-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318467/
https://www.ncbi.nlm.nih.gov/pubmed/27696084
http://dx.doi.org/10.1007/s11239-016-1429-1

Ejemplares similares